• Root node
  • Aflibercept
    • 2. In-Vitro Pharmacology
      • 2.1 In vitro-Animals
      • 2.2 In vitro-Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Pharmacokinetics
      • 3.3 Animal Toxicology
        • 3.3.1 Drug Interactions
      • 3.4 Disease Models/Xenographs
        • 3.4.1 Breast Neoplasms
        • 3.4.2 Colorectal Neoplasms
        • 3.4.3 Gastric Neoplasms
        • 3.4.4 Head and Neck Neoplasms
        • 3.4.5 Leukemia
        • 3.4.6 Lung Neoplasms
        • 3.4.7 Pancreatic Neoplasms
        • 3.4.8 Prostate Neoplasms
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Other Neoplasms
        • 5.1.2 Eye Diseases
    • 6. Adverse Effects, Safety and Tolerability
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
    • 8. Pharmacoeconomics / Quality of Life
  • Alfuzosin
    • 1. Chemistry
    • 2. In Vitro Studies
      • 2.1 In Vitro - Animal
      • 2.2 In Vitro - Human
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 AUC
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
        • 4.3.1 Food Interactions
        • 4.3.2 Influence on Cytochrome P450 System
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Benign Prostate Hyperplasia
          • 5.1.1.1 Benign Prostate Hyperplasia (since 2005)
        • 5.1.2 Acute Urine Retention
      • 5.2 Comparative Studies versus
        • 5.2.1 Adrenergic Alpha Antagonists
          • 5.2.1.1 Adrenergic Alpha Antagonists (since 2005)
          • 5.2.1.2 Doxazosin
          • 5.2.1.3 Prazosin
          • 5.2.1.4 Tamsulosin
          • 5.2.1.5 Terazosin
        • 5.2.2 Testosterone 5-alpha reductase inhibitors
          • 5.2.2.1 Finasteride
        • 5.2.3 Propranolol
        • 5.2.4 Plant extracts
      • 5.3 Pediatrics
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Alfuzosin induced
        • 6.1.1 Cardiovascular Diseases
        • 6.1.2 Edema
        • 6.1.3 Exanthema
        • 6.1.4 Eye Diseases
        • 6.1.5 Fatigue, Asthenia
        • 6.1.6 Gastrointestinal Diseases
        • 6.1.7 Hepatitis toxic
        • 6.1.8 Nervous System Diseases
        • 6.1.9 Respiratory Tract Diseases
        • 6.1.10 Urologic Diseases
        • 6.1.11 Sexual Disorders
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
      • 7.4 Reviews since 2005
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Amisulpride
    • 1. Chemistry
    • 2. In Vitro Studies
      • 2.1 In Vitro - Animal
      • 2.2 In Vitro - Human
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 AUC
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
        • 4.3.1 Influence on Cytochrome P450 System
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Schizophrenia
        • 5.1.2 Bipolar-Disorder
        • 5.1.3 Depressive-Disorder
        • 5.1.4 Delirium
        • 5.1.5 Psychotic-Disorders
      • 5.2 Comparative Studies versus
        • 5.2.1 Clozapine
        • 5.2.2 Flupenthixol
        • 5.2.3 Fluphenazine
        • 5.2.4 Haloperidol
        • 5.2.5 Olanzapine
        • 5.2.6 Quetiapine
        • 5.2.7 Risperidone
        • 5.2.8 Ziprazidone
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Amisulpride induced
        • 6.1.1 Amenorrhea
        • 6.1.2 Anxiety
        • 6.1.3 Asthenia, Fatigue
        • 6.1.4 Basal-Ganglia-Diseases
        • 6.1.5 Cardiovascular-Diseases
          • 6.1.5.1 Long-QT-Syndrome
          • 6.1.5.2 Tachycardia
          • 6.1.5.3 Torsades-de-Pointes
        • 6.1.6 Constipation
        • 6.1.7 Diarrhea
        • 6.1.8 Dizziness
        • 6.1.9 Dyskinesias
          • 6.1.9.1 Hyperkinesis
          • 6.1.9.2 Psychomotor-Agitation
        • 6.1.10 Endocrine-System-Diseases
          • 6.1.10.1 Hyperprolactinemia
        • 6.1.11 Gastrointestinal-Diseases
        • 6.1.12 Insomnia
        • 6.1.13 Nausea and Vomiting
        • 6.1.14 Neurologic-Manifestations
          • 6.1.14.1 Hallucinations
          • 6.1.14.2 Vertigo
        • 6.1.15 Pain
          • 6.1.15.1 Headache
        • 6.1.16 Sex-Disorders
        • 6.1.17 Skin-Diseases
          • 6.1.17.1 Gynecomastia
          • 6.1.17.2 Galactorrhea
        • 6.1.18 Weight-Gain
        • 6.1.19 Xerostomia
      • 6.2 Case Reports
    • 7. Somnolence
    • 8. Substance-Related-Disorders
      • 8.1 Substance-Abuse
      • 8.2 Substance-Dependence
      • 8.3 Substance-Withdrawal-Syndrome
      • 8.4 Poisoning
    • 9. Reviews
      • 9.1 Adverse Effects
      • 9.2 Practice Guidelines
      • 9.3 Therapeutic Use
    • 10. Pharmacoeconomics / Quality of Life
      • 10.1 Pharmacoeconomics
      • 10.2 Quality of life
  • AVE0010
    • 1. Chemistry and Mechanism of Action
    • 2. In-Vitro Pharmacology
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
    • 6. Adverse Effects, Safety and Tolerability
    • 7. Reviews
    • 8. Pharmacoeconomics / Quality of Life
  • Clopidogrel
    • 1. Chemistry
    • 2. In Vitro Studies
      • 2.1 In Vitro - Animal
      • 2.2 In Vitro - Human
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 AUC
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Use in prevention of
        • 5.1.1 Cerebrovascular accident
        • 5.1.2 Myocardial infarction
        • 5.1.3 Thrombosis
      • 5.2 Use in treatment of
        • 5.2.1 Coronary Disease
        • 5.2.2 Myocardial infarction
        • 5.2.3 Cerebrovascular accident
        • 5.2.4 Vascular Diseases
      • 5.3 Combination with aspirin
        • 5.3.1 Aspirin
        • 5.3.2 Ticlopidine
        • 5.3.3 Heparin
        • 5.3.4 Irbesartan
        • 5.3.5 Warfarin
        • 5.3.6 Prasugrel
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Clopidogrel induced
        • 6.1.1 Dyspepsia
        • 6.1.2 Exanthema
        • 6.1.3 Hematoma
        • 6.1.4 Hemorrhage
          • 6.1.4.1 Gastrointestinal-hemorrhage
          • 6.1.4.2 Intracranial-hemorrhage
          • 6.1.4.3 Cerebral-Hemorrhage
        • 6.1.5 Liver-Dieases
        • 6.1.6 Nausea
        • 6.1.7 Neutropenia
        • 6.1.8 Thrombocytopenia
          • 6.1.8.1 Purpura-Thrombotic-Thrombocytopenic
          • 6.1.8.2 Purpura
        • 6.1.9 Vomiting
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
      • 7.4 Reviews since 2006
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Copaxone
    • 1. Chemistry
    • 2. In-Vitro Pharmacology
      • 2.1 In vitro-Animals
      • 2.2 In vitro-Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
      • 3.3 Disease Models
        • 3.3.1 Disease Models, Autoimmune
        • 3.3.2 Disease Models, CNS Injuries
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Multiple Sclerosis
          • 5.1.1.1 Multiple Sclerosis, Relapsing-Remitting
          • 5.1.1.2 Multiple Sclerosis, Chronic Progressive
        • 5.1.2 Encephalomyelitis
      • 5.2 Comparative Studies versus
        • 5.2.1 Comparative Studies - Interferon beta - any/all
        • 5.2.2 Comparative Studies - Interferon beta-1a - Avonex
        • 5.2.3 Comparative Studies - Interferon beta-1a - Rebif
        • 5.2.4 Comparative Studies - Interferon beta-1b - Betaferon
        • 5.2.5 Comparative Studies - Interferon beta-1b - Betaseron
        • 5.2.6 Comparative Studies - IV Immunoglobulins
        • 5.2.7 Comparative Studies - Mitoxantrone
      • 5.3 Combination Studies
      • 5.4 MRI Evaluation
      • 5.5 Pediatrics
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Drug Name induced
        • 6.1.1 Pregnancy Complications
      • 6.2 Case Reports
    • 7. Reviews
      • 7.2 Practice Guidelines
    • 8. Pharmacoeconomics / Quality of Life
  • Docetaxel
    • 2. In-Vitro Pharmacology
      • 2.1 In vitro-Animals
      • 2.2 In vitro-Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Breast Neoplasms
          • 5.1.1.1 First-Line Therapy
          • 5.1.1.2 Second-Line Therapy
          • 5.1.1.3 Anthracycline Resistance
          • 5.1.1.4 Salvage Chemotherapy
        • 5.1.2 Lung Neoplasms
          • 5.1.2.1 Non-Small Cell Lung Cancer
            • 5.1.2.1.1 First-Line Therapy
            • 5.1.2.1.2 Second-Line Therapy
          • 5.1.2.2 Small Cell Lung Cancer
        • 5.1.3 Head And Neck Neoplasms
        • 5.1.4 Prostate Neoplasms
        • 5.1.5 Stomach Neoplasms
        • 5.1.6 Colorectal Neoplasms
        • 5.1.7 Melanoma
        • 5.1.8 Ovarian Neoplasms
        • 5.1.9 Liver Neoplasms
        • 5.1.10 Pancreatic Neoplasms
      • 5.3 Drug Combination Therapy
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Dronedarone
    • 1. Chemistry
    • 2. In Vitro Studies
      • 2.1 In Vitro - Animal
      • 2.2 In Vitro - Human
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 AUC
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Atrial Fibrillation
        • 5.1.2 Atrial Flutter
        • 5.1.3 Arrhythmia
      • 5.2 Comparative Studies versus
        • 5.2.1 Amiodarone
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Dronedarone induced
        • 6.1.1 Gastrointestinal Diseases
        • 6.1.2 Long QT Syndrome
        • 6.1.3 Skin diseases
        • 6.1.4 Torsades de pointes
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
    • 8. Pharmacoeconomics
  • Enoxaparin
    • 1. Chemistry
    • 2. In-Vitro Pharmacology
      • 2.1 Effects on Coagulation Process
      • 2.2 Effects on Platelet Functions
      • 2.3 Effects on Fibrinolysis
      • 2.4 Interaction with Endothelium
      • 2.5 Effects on Cell Proliferation
      • 2.6 Interaction With Lipid Metabolism
      • 2.7 Bioequivalence to Generic LMWH
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
        • 3.1.1 Antithrombotic Properties
        • 3.1.2 Bleeding Activity
        • 3.1.3 Metabolism and Kinetics
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
        • 4.1.1 Bioequivalence to Generic LMWH
      • 4.2 Pharmacokinetics
        • 4.2.1 Elderly Patients
        • 4.2.2 Hemodialysis / Renal Impairment
        • 4.2.3 Obesity
        • 4.2.4 Pregnancy
      • 4.4 Drug Interactions
    • 5. Clinical Studies
      • 5.1 In Prophylaxis of VTE
        • 5.1.1 In Medical Patients
        • 5.1.2 In Surgical Patients
          • 5.1.2.1 Bariatric Surgery
          • 5.1.2.2 Cancer Surgery
          • 5.1.2.3 General Surgery
          • 5.1.2.4 Neurosurgery
          • 5.1.2.5 Orthropedic Surgery
            • 5.1.2.5.1 Hip Arthroplasty
            • 5.1.2.5.2 Knee Arthroplasty
          • 5.1.2.6 Vascular Surgery
        • 5.1.3 In Elderly Patients
        • 5.1.4 In Children
        • 5.1.5 In Pregnant Women
        • 5.1.6 After Acute Ischemic Stroke
          • 5.1.6.1 PREVAIL Study
      • 5.2 In Major Trauma Patients
      • 5.3 In Treatment of VTE
        • 5.3.1 In Elderly Patients
        • 5.3.2 In Neonates and Infants
        • 5.3.3 In Children
      • 5.4 In Treatment of ACS
        • 5.4.1 UA/NSTEMI
          • 5.4.1.1 ACUTE I+II Studies
          • 5.4.1.2 ESSENCE Study
          • 5.4.1.3 EVET Study
          • 5.4.1.4 INTERACT Study
          • 5.4.1.5 NICE Study
          • 5.4.1.6 SYNERGY Study
          • 5.4.1.7 TIMI 11B Study
        • 5.4.2 STEMI
          • 5.4.2.1 AMI-SK Study
          • 5.4.2.2 ASSENT-3 Study
          • 5.4.2.3 ENTIRE TIMI 23 Study
          • 5.4.2.4 EXTRACT TIMI 25 Study
          • 5.4.2.5 HART II Study
          • 5.4.2.6 TETAMI Study
        • 5.4.3 PCI
      • 5.5 In Hemodialysis
      • 5.6 In Bridging Therapy
      • 5.7 In Patients with Mechanical Heart Valves
      • 5.8 In Air Travel
      • 5.9 Comparative Studies versus
        • 5.9.1 UFH
        • 5.9.2 Bivalirudin
        • 5.9.3 Fondaparinux
        • 5.9.4 Rivaroxaban
        • 5.9.5 Warfarin
      • 5.10 Drug Combination Therapy with GP IIb/IIIa Receptor Antagonists
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Drug Name induced
        • 6.1.1 Heparin Induced Thrombocytopenia (HIT)
        • 6.1.2 Intracranial Hemorrhage (ICH)
        • 6.1.3 Major Hemorrhage
        • 6.1.4 Osteoporosis
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
      • 7.4 Meta-Analysis of Clinical Trials
    • 8. Pharmacoeconomics
  • Fexofenadine
    • 1. Chemistry
    • 2. In-Vitro Pharmacology
      • 2.1 In vitro- Animals
      • 2.2 In vitro- Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Seasonal Allergic Rhinitis
        • 5.1.2 CIU
        • 5.1.3 Perennial Allergic Rhinitis
      • 5.2 Comparative Studies versus
        • 5.2.1 Comparative Studies - Loratadine
        • 5.2.2 Comparative Studies - Terfenadine
        • 5.2.3 Comparative Studies - Cetirizine
        • 5.2.4 Comparative Studies - Desloratadine
        • 5.2.5 Comparative Studies - Norastemizole
        • 5.2.6 Comparative Studies - Levocetirizine
      • 5.3 Drug Combination Therapy
        • 5.3.1 Combination with Pseudoephedrine
      • 5.4 Pediatrics
      • 5.5 Once Daily Administration
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Drug Name induced
        • 6.1.1 Effects on Driving or Flying Performance
      • 6.2 Case Reports
    • 7. Reviews
      • 7.2 Practice Guidelines
    • 8. Pharmacoeconomics / Quality of Life
  • Idraparinux
    • 1. Chemistry and Mechanism of Action
      • 1.1 Chemistry
      • 1.2 Mechanism of Action
    • 2. In-Vitro Pharmacology
      • 2.1 In vitro- Animals
      • 2.2 In vitro- Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use
        • 5.1.1 In Treatment of DVT
        • 5.1.2 In Treatment of Pulmonary Embolism
        • 5.1.3 In Stroke Prophylaxis
        • 5.1.4 In VTE Prophylaxis
      • 5.2 Comparative Studies
      • 5.3 Drug Combination Therapy
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Drug Name induced
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
    • 8. Pharmacoeconomics / Quality of Life
  • Insulin Glargine
    • 1. Chemistry
    • 2. In-Vitro Pharmacology
      • 2.1 In vitro- Animals
      • 2.2 In vitro- Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Type 1-Diabetes
        • 5.1.2 Type 2-Diabetes
        • 5.1.3 In Pediatrics
      • 5.2 Comparative Studies versus
        • 5.2.1 Insulin Detemir
        • 5.2.2 NPH Insulin
      • 5.3 Combination Therapy
        • 5.3.1 Combination with Insulin Glulisine
        • 5.3.2 Combination with NPH Insulin
        • 5.3.3 Combination with Sulfonylurea Compounds
        • 5.3.4 Combination with Metformin
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Drug Name induced
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Insulin Glulisine
    • 1. Chemistry
    • 2. In-Vitro Pharmacology
      • 2.1 In vitro- Animals
      • 2.2 In vitro- Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Type 1-Diabetes
        • 5.1.2 Type 2-Diabetes
        • 5.1.3 In Pediatrics
      • 5.2 Comparative Studies versus
        • 5.2.1 Insulin Lispro
        • 5.2.2 Regular Insulin
      • 5.3 Drug Combination Therapy
        • 5.3.1 Combination with Insulin Glargine
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Drug Name induced
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Irbesartan
    • 1. Chemistry
    • 2. In Vitro Studies
      • 2.1 In Vitro - Animal
      • 2.2 In Vitro - Human
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 AUC
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
        • 4.3.1 Food Interactions
        • 4.3.2 Influence on Cytochrome P450 System
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Hypertension
          • 5.1.1.1 Hypertension (since 2005)
        • 5.1.2 Diabetic Nephropathies
        • 5.1.3 Cardiovascular Diseases
          • 5.1.3.1 Cardiovascular Diseases (since 2005)
        • 5.1.4 Metabolic Syndrome
        • 5.1.5.Vascular Diseases
      • 5.2 Comparative Studies versus
        • 5.2.1 Sartans
          • 5.2.1.1 Candesartan
          • 5.2.1.2 Eprosartan
          • 5.2.1.3 Losartan
          • 5.2.1.4 Olmesartan
          • 5.2.1.5 Telmisartan
          • 5.2.1.6 Valsartan
        • 5.2.2 ACEI
        • 5.2.3 Calcium Channel Blockers
      • 5.3 Combination with hydrochlorothiazide
      • 5.4 Pediatrics
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Irbesartan induced
        • 6.1.1 Anxiety
        • 6.1.2 Cardiovascular Diseases
        • 6.1.3 Edema
        • 6.1.4 Eye Diseases
        • 6.1.5 Fatigue, Asthenia
        • 6.1.6 Fever
        • 6.1.7 Gastrointestinal Diseases
        • 6.1.8 Hematologic Diseases
        • 6.1.9 Hemorrhage
        • 6.1.10 Liver Diseases
        • 6.1.11 Musculoskeletal Diseases
        • 6.1.12 Nasopharyngitis
        • 6.1.13 Nervous System Diseases
        • 6.1.14 Nutritional and Metabolic Diseases
        • 6.1.15 Respiratory Diseases
        • 6.1.16 Skin and Connective Tissue Diseases
        • 6.1.17 Urologic Diseases
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
      • 7.4 Reviews since 2006
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Oxaliplatin
    • 1. Chemistry
    • 2. In vitro studies
      • 2.1 In vitro- Animals
      • 2.2 In vitro- Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Colorectal-neoplasms
          • 5.1.1.1 Colorectal-neoplasms (since 2005)
        • 5.1.2 Liver-neoplasms
        • 5.1.3 Ovarian-neoplasms
        • 5.1.4 Head-and-Neck-neoplasms
        • 5.1.5 Lung-neoplasms
        • 5.1.6 Lymphoma-Non-Hodgkin
        • 5.1.7. Breast-neoplasms
        • 5.1.8. Kidney-neoplasms
      • 5.2 Comparative Studies versus
        • 5.2.1 Cisplatin
        • 5.2.2 Carboplatin
        • 5.2.3 Tetraplatin
        • 5.2.4 Gemcitabine
      • 5.3 Drug Combination Therapy
        • 5.3.1 FOLFOX Regimen
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Oxaliplatin induced
        • 6.1.1 Diarrhea
        • 6.1.2 Gastrointestinal Diseases
        • 6.1.3 Hand and Foot Syndrome
        • 6.1.4 Neutropenia
        • 6.1.5 Nausea
        • 6.1.6 Peripheral Nervous System Diseases
        • 6.1.7 Thrombocytopenia
        • 6.1.8 Vomiting
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Riluzole
    • 1. Chemistry
    • 2. In-Vitro Pharmacology
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Amyotrophic Lateral Sclerosis
        • 5.1.2 Huntington's Disease
        • 5.1.3 Parkinson Disease
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Case Reports
    • 7. Reviews
      • 7.2 Practice Guidelines
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of Life
  • Rimonabant
    • 1. Chemistry
    • 2. In Vitro Studies
      • 2.1 In Vitro - Animal
      • 2.2 In Vitro - Human
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacokinetics
      • 4.2 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Obesity
        • 5.1.2 Metabolic Diseases
          • 5.1.2.1 Metabolic-Syndrome-X
          • 5.1.2.2 Diabetes Mellitus
            • 5.1.2.2.1 Diabetes Mellitus Type 2
        • 5.1.3 Smoking Cessation
      • 5.2 Comparative Studies versus
        • 5.2.1 WIN552122
        • 5.2.2 Tetrahydrocannabinol
        • 5.2.3 SR144528
        • 5.2.4 AM251
        • 5.2.5 Anandamide
      • 5.3 Combination
      • 5.4 Pediatrics
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Rimonabant induced
        • 6.1.1 Anxiety
        • 6.1.2 Diarrhea
        • 6.1.3 Dizziness
        • 6.1.4 Gastrointestinal-Diseases
        • 6.1.5 Infection
        • 6.1.6 Mood-Disorders and Depression
          • 6.1.6.1 Depressive disorders
          • 6.1.6.2 Depression
        • 6.1.7 Multiple-Sclerosis
        • 6.1.8 Nausea and Vomiting
        • 6.1.9 Pain
          • 6.1.9.1 Headache
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Practice Guidelines
      • 7.3 Therapeutic Use
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Risedronate
    • 1. Chemistry
    • 2. In-Vitro Pharmacology
      • 2.1 In vitro-Animals
      • 2.2 In vitro-Humans
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
      • 3.3 Disease Models
        • 3.3.1 Disease Models, Autoimmune
        • 3.3.2 Disease Models, CNS Injuries
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 Pharmacology
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Paget's Disease
        • 5.1.2 Bone Loss in Postmenopausal Healthy Women
        • 5.1.3 Postmenopausal Osteoporosis
        • 5.1.4 Corticosteroid-induced Osteoporosis
        • 5.1.5 Fractures in Postmenopausal Osteoporosis
        • 5.1.6 Fractures in Corticosteroid-induced Bone Loss
        • 5.1.7 Multiple Myeloma
      • 5.2 Comparative Studies versus
        • 5.2.1 Alendronate
        • 5.2.2 Etinodrate
        • 5.2.3 Ibandronate
        • 5.2.4 Zoledronate
      • 5.3 Combination Studies
        • 5.3.1 Combination with Estrogen
      • 5.4 Once Weekly Therapy
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Drug Name induced
      • 6.2 Case Reports
    • 7. Reviews
      • 7.2 Practice Guidelines
    • 8. Pharmacoeconomics / Quality of Life
  • Telithromycin
      • 1.3 Mechanism of Resistance
    • 2. In-Vitro Pharmacology
      • 2.1 Antibacterial Activity against
        • 2.1.1 Chlamydia (Chlamydophila) pneumoniae
        • 2.1.2 Haemophilus influenzae
        • 2.1.3 Legionella pneumophila
        • 2.1.4 Moraxella (Branhamella) catarrhalis
        • 2.1.5 Mycoplasma pneumoniae
        • 2.1.6 Staphylococcus aureus
        • 2.1.7 Streptococcus pneumoniae (Pneumococcus)
      • 2.2 Postantibiotic Effect
      • 2.3 Intracellular Uptake and Activity
      • 2.4 Development of Resistance against
        • 2.4.1 Streptococcus pneumoniae (Pneumococcus)
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 AUC/MIC Ratio
      • 4.2 Pharmacokinetics
        • 4.2.1 Concentrations in Respiratory Tract Fluids/Tissues
      • 4.3 Drug Interactions
        • 4.3.1 Food Interactions
        • 4.3.2 Influence on Cytochrome P450 System
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Community-Acquired Pneumonia (CAP)
          • 5.1.1.1 Atypical Pneumonia
        • 5.1.2 Acute Exacerbation of Chronic Bronchitis (AECB)
        • 5.1.3 Acute Bacterial Sinusitis (ABS)
        • 5.1.4 Pharyngitis/Tonsillitis
        • 5.1.5. Asthma
      • 5.2 Comparative Studies versus
        • 5.2.1 Amoxicillin
        • 5.2.2 Amoxicillin/Clavulanic Acid
        • 5.2.3 Cefuroxime Axetil
        • 5.2.4 Clarithromycin
        • 5.2.5 Moxifloxacin
        • 5.2.6 Penicillin
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Telithromycin induced
        • 6.1.1 Cardiovascular Diseases
        • 6.1.2 Central Nervous System Diseases
        • 6.1.3 Eye Diseases
        • 6.1.4 Gastrointestinal Diseases
        • 6.1.5 Liver Diseases
        • 6.1.6 Myasthenia Gravis
      • 6.2 Case Reports
    • 7. Reviews
      • 7.1 Adverse Effects
      • 7.2 Antibacterial Activity
      • 7.3 Practice Guidelines
      • 7.4 Therapeutic Use
    • 8. Pharmacoeconomics / Quality of Life
      • 8.1 Pharmacoeconomics
      • 8.2 Quality of life
  • Zolpidem
    • 1. Chemistry
    • 2. In Vitro Studies
      • 2.1 In Vitro - Animal
      • 2.2 In Vitro - Human
    • 3. Animal Pharmacology and Toxicology
      • 3.1 Animal Pharmacology
      • 3.2 Animal Toxicology
    • 4. Human Pharmacology, Pharmacokinetics and Drug Interactions
      • 4.1 AUC
      • 4.2 Pharmacokinetics
      • 4.3 Drug Interactions
        • 4.3.1 Food Interactions
        • 4.3.2 Influence on Cytochrome P450 System
    • 5. Clinical Studies
      • 5.1 Therapeutic use in treatment of
        • 5.1.1 Sleep-Disorders
          • 5.1.1.1 Insomnia
        • 5.1.2 Catatonia
      • 5.2 Comparative Studies versus
        • 5.2.1 Benzodiazepines
          • 5.2.1.1 Diazepam
          • 5.2.1.2 Flunitrazepam
          • 5.2.1.3 Flurazepam
          • 5.2.1.4 Midazolam
          • 5.2.1.5 Temazepam
        • 5.2.2 Zaleplon
        • 5.2.3 Zopiclone
      • 5.3 As-Needed Administration
      • 5.4 Modified-Release
    • 6. Adverse Effects, Safety and Tolerability
      • 6.1 Zolpidem induced
        • 6.1.1 Asthenia, Fatigue
        • 6.1.2 Cognition-Disorders
        • 6.1.3 Diarrhea
        • 6.1.4 Dizziness
        • 6.1.5 Gastrointestinal-Diseases
        • 6.1.6 Hypotension
        • 6.1.7 Infection
        • 6.1.8 Memory-Disorders and Amnesia
        • 6.1.9 Nausea and Vomiting
        • 6.1.10 Nightmares
        • 6.1.11 Neurologic-Manifestations
          • 6.1.11.1 Hallucinations
          • 6.1.11.2 Vertigo
          • 6.1.11.3 Taste-Disorders
        • 6.1.12 Nervous-System-Diseases
        • 6.1.13 Peripheral-Nervous-System-Diseases
        • 6.1.14 Pain
          • 6.1.14.1 Abdominal-Pain
          • 6.1.14.2 Headache
        • 6.1.15 Respiration-Disorders
        • 6.1.16 Respiratory-Sounds
        • 6.1.17 Skin-Diseases
          • 6.1.17.1 Pruritus
        • 6.1.18 Speech-Disorders
        • 6.1.19 Tachycardia
        • 6.1.20 Xerostomia
      • 6.2 Case Reports
    • 7. Somnolence and Residual Effects
      • 7.1 Residual Effects
    • 8. Substance-Related-Disorders
      • 8.1 Substance-Abuse
      • 8.2 Substance-Dependence
      • 8.3 Substance-Withdrawal-Syndrome
      • 8.4 Poisoning
    • 9. Reviews
      • 9.1 Adverse Effects
      • 9.2 Practice Guidelines
      • 9.3 Therapeutic Use
    • 10. Pharmacoeconomics / Quality of Life
      • 10.1 Pharmacoeconomics
      • 10.2 Quality of life